Merck’s WELIREG Advances with FDA Priority Review in Early RCC Supported by Compelling DFS Evidence; Roche’s Fenebrutinib Delivers Another Phase III Victory; Positive CHMP Opinion Paves Way for Novartis’ Remibrutinib in CSU Treatment; Pfizer’s BRAFTOVI Regimen Gains FDA’s Full Nod for Initial Treatment of Metastatic Colorectal Cancer; VYVGART Achieves Positive Results in Phase 3 ADAPT OCULUS Trial

Merck’s WELIREG Secures Priority FDA Review for Adjuvant Treatment in Early RCC Driven by Pivotal DFS Improvement

Merck announced landmark results from its Phase 3 LITESPARK-022 trial, which evaluated the combination of KEYTRUDA (pembrolizumab) and WELIREG (belzutifan) as an adjuvant treatment for patients with certain types of earlier-stage renal cell carcinoma (RCC) at high risk of recurrence following nephrectomy. The study demonstrated that the combination therapy significantly reduced the risk of disease recurrence or death by 28% (Hazard Ratio = 0.72) compared to KEYTRUDA monotherapy. 

This is particularly significant because KEYTRUDA alone is already a standard-of-care adjuvant treatment; adding WELIREG, a first-in-class HIF-2α inhibitor, represents a potential new standard that could further improve outcomes in a disease where roughly 40% of patients traditionally experience recurrence within five years. The primary endpoint of disease-free survival (DFS) showed a notable trend, with estimated 24-month DFS rates of 80.7% for the combination versus 73.7% for the monotherapy arm. 

Based on these data, the U.S. FDA has accepted supplemental applications for WELIREG and KEYTRUDA for priority review. From a safety perspective, the profile of the combination was generally consistent with the known profiles of each drug. While the combination arm saw a higher incidence of Grade 3 or greater treatment-emergent adverse events (52.1% vs. 30.2%), most cases of anemia and hypoxia, side effects specific to WELIREG’s mechanism, were manageable, and discontinuation rates due to adverse events remained low. 

This trial marks the first time a combination of an immunotherapy and an HIF-2α inhibitor has shown superior efficacy over immunotherapy alone in the adjuvant setting, potentially redefining the treatment landscape for kidney cancer patients by intervening earlier in the disease progression when the possibility of a cure is highest.

Roche’s Fenebrutinib Achieves Another Phase III Success

Roche reported positive topline results from its late-stage clinical trials for fenebrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor being developed for the treatment of relapsing multiple sclerosis (RMS). The Swiss pharmaceutical giant confirmed that fenebrutinib met its primary goal in the FENhance I and II trials, demonstrating a statistically significant reduction in the annualized relapse rate (ARR) compared to the active comparator, Aubagio (teriflunomide). 

Specifically, the drug reduced the rate of relapses by 51% over at least 96 weeks, matching the high bar set for modern multiple sclerosis therapies. Fenebrutinib is designed to target both B-cells and microglia, potentially addressing both the acute inflammation that causes relapses and the chronic “smoldering” inflammation within the brain that leads to long-term disability progression. 

This dual action is a major focus for Roche as it seeks to offer an oral alternative that matches or exceeds the efficacy of its own blockbuster injectable, OCREVUS. Despite the efficacy success, the news was met with some caution regarding safety: the company reported two cases of drug-induced liver injury across the studies, and eight deaths occurred during the trials (though causes and timing varied). These findings come at a critical time for the BTK inhibitor class, as competitors like Sanofi have recently faced regulatory rejections due to liver safety concerns. 

Roche maintains that the benefit-risk profile remains positive and plans to submit the comprehensive data package, including results from a third trial in primary progressive MS, to global regulatory authorities. If approved, fenebrutinib would provide a convenient, highly effective oral option for the millions living with MS, though its path will likely depend on the FDA’s scrutiny of its long-term safety data.

Novartis’ Remibrutinib Receives Regulatory Boost with CHMP’s Positive Opinion

Novartis received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending the approval of remibrutinib for adult patients with chronic spontaneous urticaria (CSU) who have an inadequate response to H1-antihistamines. Remibrutinib is a highly selective, oral BTK inhibitor discovered and developed by Novartis. 

The CHMP’s recommendation is primarily supported by data from the REMIX-1 and REMIX-2 Phase 3 trials, which showed that the drug provides rapid and sustained relief from the debilitating itch and hives associated with CSU. Notably, patients treated with remibrutinib experienced symptom improvement as early as the first week of treatment, and these benefits were maintained through 52 weeks. 

For the nearly 4 million people in Europe living with CSU, more than half of whom do not achieve control with standard antihistamines, this oral option represents a significant therapeutic advancement. Unlike some other BTK inhibitors that have struggled with safety issues, remibrutinib demonstrated a favorable safety profile in its trials, with no liver safety signals observed over the one-year study period. 

The drug is already approved in the U.S. and China under the brand name RHAPSIDO. Beyond CSU, Novartis is also exploring remibrutinib for other conditions, including food allergies and chronic inducible urticaria, with Phase 3 results for peanut allergy expected later this year. Following this positive CHMP opinion, a final marketing authorization decision from the European Commission is expected in the coming months, which would make remibrutinib the first targeted oral therapy of its kind available for CSU patients in Europe, offering a new path for those whose daily lives are severely disrupted by unpredictable skin flares.

Pfizer’s BRAFTOVI Combination Regimen Receives Full FDA Approval for First-Line Treatment of Metastatic Colorectal Cancer

Pfizer announced that the U.S. FDA has granted full approval to BRAFTOVI (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy (either mFOLFOX6 or FOLFIRI) for the first-line treatment of adult patients with metastatic colorectal cancer (mCRC) harboring the BRAF V600E mutation. This decision converts an earlier accelerated approval into a full approval and significantly expands the treatment options for this aggressive, hard-to-treat patient population. 

The approval is anchored by the Phase 3 BREAKWATER trial, which demonstrated that the BRAFTOVI-based triplet regimen delivered a 47% reduction in the risk of disease progression or death and a 51% reduction in the risk of death compared to standard chemotherapy with or without bevacizumab. Median overall survival for patients on the BRAFTOVI regimen reached 30.3 months, a striking improvement over the 15.1 months observed in the control group. 

BRAF V600E mutations occur in approximately 8-12% of mCRC cases and are typically associated with a very poor prognosis; historically, these patients have had few effective targeted options in the first-line setting. By blocking the MAPK signaling pathway, BRAFTOVI targets the specific driver of the tumor’s growth. The safety profile remained consistent with previous studies, though the triplet regimen was associated with side effects such as nausea, fatigue, and peripheral neuropathy. 

Pfizer emphasized that this approval establishes a new standard of care, providing oncologists with a biomarker-driven, highly effective strategy to use from the very start of treatment. This regulatory milestone reinforces Pfizer’s commitment to precision oncology and offers a meaningful survival advantage to thousands of patients facing one of the most challenging forms of colorectal cancer.

argenx Announces Successful Phase 3 ADAPT OCULUS Trial Results for VYVGART in Ocular Myasthenia Gravis

Argenx announced positive topline results from its Phase 3 ADAPT OCULUS trial, evaluating VYVGART (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of ocular myasthenia gravis (oMG). The study successfully met its primary endpoint, with VYVGART-treated patients showing a statistically significant improvement in the Myasthenia Impairment Index (MGII) ocular scores at Week 4 compared to those receiving a placebo (p=0.012). 

Ocular MG is a form of the autoimmune disease that specifically affects the muscles controlling the eyes and eyelids, leading to double vision and drooping eyelids that can severely impair vision and independence. While many patients with generalized MG (gMG) also have ocular symptoms, ADAPT OCULUS is the first registrational study specifically designed to evaluate a targeted therapy for the ocular-only presentation of the disease. 

The success of this trial is a key pillar of Argenx’s “Vision 2030” strategy, which aims to expand the utility of its FcRn-blocker franchise across multiple indications. The company plans to submit a supplemental Biologics License Application (sBLA) to the FDA to include oMG in VYVGART’s label, which already includes generalized MG and CIDP. In addition to the clinical success, Argenx recently reported preliminary full-year 2025 financial results showing 90% year-over-year growth, with global product net sales reaching $4.15 billion. 

The company is currently treating approximately 19,000 patients worldwide and expects several more Phase 3 readouts in 2026, including for multifocal motor neuropathy (MMN). These clinical and financial milestones highlight Argenx’s transition from a biotech innovator to a profitable commercial powerhouse, with VYVGART continuing to redefine the standard of care for patients with severe autoimmune neuromuscular diseases.